Finding peptides to deliver drugs directly to the eye for treating uveitis
Identification of eye-homing peptides and their use for targeted liposomal drug delivery in posterior uveitis
This study is looking for better ways to treat posterior uveitis, a condition that can harm your vision, by finding special tiny proteins that help deliver medicine right to the eye while causing fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10612913 on NIH RePORTER |
What this research studies
This research focuses on understanding and treating posterior uveitis, a chronic autoimmune disease that can lead to vision impairment and blindness. The team aims to identify specific peptides that can target the eye's blood vessels, allowing for more effective delivery of medications directly to the affected area while minimizing side effects. By using advanced techniques like phage peptide library screening, they hope to discover new ways to enhance drug efficacy and reduce systemic toxicity. This approach could lead to better treatment options for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with posterior uveitis, particularly those with autoimmune origins.
Not a fit: Patients with non-autoimmune forms of uveitis or those without any eye-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective treatments for posterior uveitis, potentially preserving vision and improving quality of life.
How similar studies have performed: While the approach of using targeted peptides for drug delivery is innovative, similar strategies have shown promise in other areas of medicine, suggesting potential for success in this context.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Moudgil, Kamal D — University of Maryland Baltimore
- Study coordinator: Moudgil, Kamal D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.